Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 3 5Phase 1 3Phase 4 1

Status

Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 9NIH 3INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Treatment-Refractory Solid Tumors 2Bites and Stings 1

Interventions

pembrolizumab 301Paclitaxel 206Carboplatin 199Gemcitabine 173Cisplatin 138Docetaxel 137Cyclophosphamide 135Nivolumab 129Bevacizumab 118Injections 111fludarabine 95atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 70Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × Hydroxyurea × Clear all
NCT07190833 2026-04-09

A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)

Bionoxx Inc.

Phase 1 Recruiting
27 enrolled
Other solid neoplasm

Treatment-Refractory Solid Tumors

NCT07170592 2026-04-07

A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients

Bionoxx Inc.

Phase 1 Not yet recruiting
24 enrolled
Other solid neoplasm

Treatment-Refractory Solid Tumors

NCT06063317 2026-03-06

OASIS

Imugene Limited

Phase 1 Terminated
25 enrolled

Bites and Stings

Data powered by HemOnc (CC BY 4.0) Colophon âš¡